

Brunangelo Falini

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5840653/brunangelo-falini-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

360
papers

29,169
citations

81
h-index

165
g-index

381
ext. papers

32,443
ext. citations

7
avg, IF

6.27
L-index

#	Paper	IF	Citations
360	How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors.. <i>Blood</i> , 2022 ,	2.2	2
359	Choroidal vasculature analysis in MEK inhibitor-associated retinopathy.. <i>European Journal of Ophthalmology</i> , 2022 , 11206721221081471	1.9	0
358	Identification of novel STAT5B mutations and characterization of TCR β signatures in CD4+ T-cell large granular lymphocyte leukemia.. <i>Blood Cancer Journal</i> , 2022 , 12, 31	7	1
357	Hairy cell leukaemia with low CD103 expression: A rare but important diagnostic pitfall.. <i>British Journal of Haematology</i> , 2022 ,	4.5	
356	Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice. <i>Leukemia</i> , 2021 , 35, 1949-1963	10.7	6
355	A Comprehensive and Systematic Analysis of Minimal Residual Disease (MRD) Monitoring in Follicular Lymphoma: Results from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial. <i>Blood</i> , 2021 , 138, 41-41	2.2	
354	CD123 and CD33 Co-Targeting By Balanced Signaling on CAR-CIK Cells Reduces Potential Off-Target Toxicity While Preserving the Anti-Leukemic Activity of Acute Myeloid Leukemia. <i>Blood</i> , 2021 , 138, 1699-1699	2.2	2
353	Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06. <i>Haematologica</i> , 2021 , 106, 2578-2587	6.6	7
352	Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia. <i>Blood Advances</i> , 2021 , 5, 1199-1208	7.8	11
351	Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial. <i>Leukemia</i> , 2021 , 35, 3314-3318	10.7	9
350	Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML. <i>Leukemia</i> , 2021 , 35, 2552-2562	10.7	10
349	Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field. <i>Leukemia</i> , 2021 , 35, 3113-3126	10.7	9
348	Dissecting Clonal Hematopoiesis in Tissues of Classical Hodgkin Lymphoma Patients. <i>Blood Cancer Discovery</i> , 2021 , 2, 216-225	7	2
347	Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia. <i>New England Journal of Medicine</i> , 2021 , 384, 1810-1823	59.2	28
346	Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. <i>Leukemia</i> , 2021 , 35, 1864-1872	10.7	13
345	BCOR gene alterations in hematological diseases. <i>Blood</i> , 2021 ,	2.2	2
344	Rifaximin use favoured micafungin-resistant <i>Candida</i> spp. infections in recipients of allogeneic hematopoietic cell transplantation. <i>Annals of Hematology</i> , 2021 , 100, 2375-2380	3	2

343	Actinomycin D Targets NPM1c-Primed Mitochondria to Restore PML-Driven Senescence in AML Therapy. <i>Cancer Discovery</i> , 2021 ,	24.4	9
342	Richter's transformation in the heart. <i>Lancet Oncology, The</i> , 2021 , 22, e341	21.7	1
341	How I diagnose and treat NPM1-mutated AML. <i>Blood</i> , 2021 , 137, 589-599	2.2	13
340	CD123 Is Consistently Expressed on -Mutated AML Cells. <i>Cancers</i> , 2021 , 13,	6.6	6
339	NOVEL NPM1 EXON 5 MUTATIONS AND GENE FUSIONS LEADING TO ABERRANT CYTOPLASMIC NUCLEOPHOSMIN IN AML. <i>Blood</i> , 2021 ,	2.2	5
338	Frequent traces of EBV infection in Hodgkin and non-Hodgkin lymphomas classified as EBV-negative by routine methods: expanding the landscape of EBV-related lymphomas. <i>Modern Pathology</i> , 2020 , 33, 2407-2421	9.8	16
337	NPM1-mutated acute myeloid leukemia: from bench to bedside. <i>Blood</i> , 2020 , 136, 1707-1721	2.2	52
336	Multicenter Long Term Follow-up in Hairy Cell Leukemia Patients Treated with Cladribine: A Thirty-Year Experience. <i>Blood</i> , 2020 , 136, 32-33	2.2	1
335	ARPIR: automatic RNA-Seq pipelines with interactive report. <i>BMC Bioinformatics</i> , 2020 , 21, 574	3.6	2
334	Enasidenib and ivosidenib in AML. <i>Minerva Medica</i> , 2020 , 111, 411-426	2.2	7
333	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. <i>Lancet Haematology,the</i> , 2020 , 7, e737-e745	14.6	223
332	New treatment options in hairy cell leukemia with focus on BRAF inhibitors. <i>Hematological Oncology</i> , 2019 , 37 Suppl 1, 30-37	1.3	15
331	Flower cells of tropical descent: a challenging case of adult T-cell leukemia/lymphoma. <i>Tumori</i> , 2019 , 105, NP38-NP42	1.7	2
330	Getting away with phase transition: NPM1-mutated bone myeloid sarcoma mimicking Ewing sarcoma. <i>Annals of Hematology</i> , 2019 , 98, 2017-2018	3	1
329	Hairy cell leukaemia mimicking multiple myeloma. <i>Lancet Oncology, The</i> , 2019 , 20, e187	21.7	3
328	Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia. <i>Oncotarget</i> , 2019 , 10, 869-882	3.3	17
327	Identification of a Chromatin-Splicing Mutational Signature to Define Secondary Acute Myeloid Leukemia: A Report from the Northern Italy Leukemia Group (NILG) Prospective Trial 02/06. <i>Blood</i> , 2019 , 134, 1443-1443	2.2	1
326	Regulatory T Cell Adoptive Immunotherapy Promotes B Cell Immunity after Haploidentical Transplantation. <i>Blood</i> , 2019 , 134, 1917-1917	2.2	

325	GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations. <i>Leukemia</i> , 2019 , 33, 1827-1832	10.7	8
324	Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML. <i>Blood Advances</i> , 2019 , 3, 1103-1117	7.8	11
323	Germline NPM1 mutations lead to altered rRNA 2'-O-methylation and cause dyskeratosis congenita. <i>Nature Genetics</i> , 2019 , 51, 1518-1529	36.3	40
322	Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target. <i>Haematologica</i> , 2019 , 104, 729-737	6.6	33
321	IDH1-R132 changes vary according to NPM1 and other mutations status in AML. <i>Leukemia</i> , 2019 , 33, 1043-1047	10.7	9
320	Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma. <i>Blood</i> , 2018 , 131, 2454-2465	24.65	89
319	IDH1R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategies. <i>Leukemia</i> , 2018 , 32, 1249-1253	10.7	10
318	A BRAF-mutated case of hairy cell leukaemia lacking Annexin-A1 expression. <i>British Journal of Haematology</i> , 2018 , 183, 702	4.5	2
317	Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates. <i>Journal of Clinical Investigation</i> , 2018 , 128, 4260-4279	15.9	61
316	How Adoptive Immunotherapy with Conventional T and Regulatory T Cells Exerts a GvL Effect without GvHD, after Haploidentical Hematopoietic Transplantation. <i>Blood</i> , 2018 , 132, 3333-3333	2.2	1
315	Haploidentical Transplantation with Regulatory and Conventional T Cells Improves Outcome of Patients Affected By Acute Myeloid Leukemia with Complex Karyotype and/or Monosomy 7/Del(7q). <i>Blood</i> , 2018 , 132, 2183-2183	2.2	0
314	Clonal Hematopoiesis Leading to AITL and NPM1-Mutated AML. <i>New England Journal of Medicine</i> , 2018 , 379, 2184-2185	59.2	
313	Recent advances in understanding and managing hairy cell leukemia. <i>F1000Research</i> , 2018 , 7,	3.6	2
312	High-Risk Clonal Hematopoiesis as the Origin of AITL and NPM1-Mutated AML. <i>New England Journal of Medicine</i> , 2018 , 379, 981-984	59.2	32
311	Mutant NPM1 Maintains the Leukemic State through HOX Expression. <i>Cancer Cell</i> , 2018 , 34, 499-512.e9	24.3	114
310	Blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia: a shared clonal origin. <i>Leukemia</i> , 2017 , 31, 1238-1240	10.7	24
309	Management of anaemia in oncohaematological patients treated with biosimilar epoetin alfa: results of an Italian observational, retrospective study. <i>Therapeutic Advances in Medical Oncology</i> , 2017 , 9, 22-32	5.4	6
308	Persistent Immune Stimulation Exacerbates Genetically Driven Myeloproliferative Disorders via Stromal Remodeling. <i>Cancer Research</i> , 2017 , 77, 3685-3699	10.1	16

307	Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. <i>Blood</i> , 2017 , 129, 553-560	2.2	126
306	Genomics of Hairy Cell Leukemia. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1002-1010	2.2	42
305	A scale of "bad" co-mutations in -driven AML. <i>Blood</i> , 2017 , 130, 1877-1879	2.2	5
304	Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients. <i>Haematologica</i> , 2017 , 102, 1718-1726	6.6	24
303	First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2017 , 130, 99-99	2.2	47
302	Human monocyte-derived dendritic cells exposed to hyperthermia show a distinct gene expression profile and selective upregulation of. <i>Oncotarget</i> , 2017 , 8, 60826-60840	3.3	14
301	Acute Myeloid Leukemia with Mutated NPM1 Is Dependent on the Cytoplasmic Localization of NPM1c. <i>Blood</i> , 2017 , 130, 877-877	2.2	
300	The Mechanisms By Which Mutant-NPM1 Uncouples Differentiation from Proliferation Are Reversed By Several Drugs, Enabling Rational Multi-Component Non-Cytotoxic Differentiation Therapy. <i>Blood</i> , 2017 , 130, 878-878	2.2	
299	The genetics of nodal marginal zone lymphoma. <i>Blood</i> , 2016 , 128, 1362-73	2.2	88
298	Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts. <i>Blood</i> , 2016 , 127, 221-32	2.2	65
297	BRAF V600E mutation in hairy cell leukemia: from bench to bedside. <i>Blood</i> , 2016 , 128, 1918-1927	2.2	57
296	15. Anaplastic large cell lymphoma 2016 , 285-310		
295	New mechanism of lymphoma-induced bone marrow aplasia. <i>Annals of Hematology</i> , 2016 , 95, 1013-5	3	
294	Vemurafenib Plus Rituximab in Hairy Cell Leukemia: A Promising Chemotherapy-Free Regimen for Relapsed or Refractory Patients. <i>Blood</i> , 2016 , 128, 1214-1214	2.2	5
293	Identification and Characterization of Novel Rare Nucleophosmin (NPM1) Gene Mutations in Acute Myeloid Leukemia (AML) By a Combinatorial Approach of Immunohistochemistry and Molecular Analyses. <i>Blood</i> , 2016 , 128, 1717-1717	2.2	3
292	The Mechanism By Which Mutant Nucleophosmin (NPM1) Creates Leukemic Self-Renewal Is Readily Reversed. <i>Blood</i> , 2016 , 128, 444-444	2.2	4
291	A Distributed International Patient Data Registry for Hairy Cell Leukemia. <i>Blood</i> , 2016 , 128, 5986-5986	2.2	
290	All-trans retinoic acid (ATRA) in non-promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low-dose Ara-C in three elderly patients with -mutated AML unfit for intensive chemotherapy and review of the literature. <i>Clinical Case Reports (discontinued)</i> , 2016 , 4, 1138-1146	0.7	7

289	A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study. <i>Haematologica</i> , 2016 , 101, 1544-1552	6.6	44
288	Transformation of IGHV4-34+ hairy cell leukaemia-variant with U2AF1 mutation into a clonally-related high grade B-cell lymphoma responding to immunochemotherapy. <i>British Journal of Haematology</i> , 2016 , 173, 491-5	4.5	3
287	A case of concomitant chronic lymphocytic leukaemia and hairy cell leukaemia evaluated for IGHV-D-J rearrangements and BRAF-V600E mutation: lack of evidence for a common origin. <i>British Journal of Haematology</i> , 2016 , 174, 329-31	4.5	4
286	Acute Myeloid Leukemia With Recurrent Genetic Abnormalities Other Than Translocations. <i>American Journal of Clinical Pathology</i> , 2015 , 144, 19-28	1.9	6
285	Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma. <i>Cancer Cell</i> , 2015 , 27, 744	24.3	2
284	A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation. <i>Leukemia</i> , 2015 , 29, 1390-401	10.7	32
283	Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. <i>Cancer Cell</i> , 2015 , 27, 516-32	24.3	283
282	Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells. <i>Blood</i> , 2015 , 125, 3455-65	2.2	98
281	Dactinomycin in NPM1-Mutated Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2015 , 373, 1180-2	59.2	42
280	Impact of genomics in the clinical management of patients with cytogenetically normal acute myeloid leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2015 , 28, 90-7	4.2	8
279	NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. <i>Leukemia and Lymphoma</i> , 2015 , 56, 3222-6	1.9	17
278	Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. <i>New England Journal of Medicine</i> , 2015 , 373, 1733-47	59.2	215
277	Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications. <i>Leukemia</i> , 2015 , 29, 269-78	10.7	36
276	BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity. <i>Blood</i> , 2015 , 125, 1207-16	2.2	66
275	Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics. <i>British Journal of Haematology</i> , 2015 , 170, 305-22	4.5	28
274	Immunohistochemical differentiation between follicular lymphoma and nodal marginal zone lymphoma--combined performance of multiple markers. <i>Haematologica</i> , 2015 , 100, e358-60	6.6	16
273	Differences among young adults, adults and elderly chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2015 , 26, 185-192	10.3	48
272	"Designed" grafts for HLA-haploidentical stem cell transplantation. <i>Blood</i> , 2014 , 123, 967-73	2.2	63

271	HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. <i>Blood</i> , 2014 , 124, 638-44	2.2	286
270	Identification of novel DNA-damage tolerance genes reveals regulation of translesion DNA synthesis by nucleophosmin. <i>Nature Communications</i> , 2014 , 5, 5437	17.4	38
269	Clustering of genomic breakpoints at the MLL locus in therapy-related acute leukemia with t(4;11)(q21;q23). <i>Genes Chromosomes and Cancer</i> , 2014 , 53, 248-54	5	5
268	Subclonal evolution of a classical Hodgkin lymphoma from a germinal center B-cell-derived mantle cell lymphoma. <i>International Journal of Cancer</i> , 2014 , 134, 832-43	7.5	13
267	Efficacy and Safety of the BRAF Inhibitor Vemurafenib in Hairy Cell Leukemia Patients Refractory to or Relapsed after Purine Analogs: A Phase-2 Italian Clinical Trial. <i>Blood</i> , 2014 , 124, 150-150	2.2	2
266	The Coding Genome of Nodal Marginal Zone Lymphoma Reveals Recurrent Molecular Alterations of PTPRD and Other Jak/Stat Signaling Genes. <i>Blood</i> , 2014 , 124, 705-705	2.2	7
265	Identification of a New Subclass of ALK Negative Anaplastic Large Cell Lymphoma Expressing Aberrant Levels of ERBB4 Transcripts. <i>Blood</i> , 2014 , 124, 1679-1679	2.2	
264	SAVI: a statistical algorithm for variant frequency identification. <i>BMC Systems Biology</i> , 2013 , 7 Suppl 2, S2	3.5	29
263	Nucleophosmin mutations alter its nucleolar localization by impairing G-quadruplex binding at ribosomal DNA. <i>Nucleic Acids Research</i> , 2013 , 41, 3228-39	20.1	67
262	Mutational landscape of AML with normal cytogenetics: biological and clinical implications. <i>Blood Reviews</i> , 2013 , 27, 13-22	11.1	74
261	IL-17-producing CD4-CD8- T cells are expanded in the peripheral blood, infiltrate salivary glands and are resistant to corticosteroids in patients with primary Sjogren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 286-92	2.4	73
260	Nucleophosmin mutations in acute myeloid leukemia: a tale of protein unfolding and mislocalization. <i>Protein Science</i> , 2013 , 22, 545-56	6.3	69
259	Nodal reactive and neoplastic proliferation of monocytoid and marginal zone B cells: an immunoarchitectural and molecular study highlighting the relevance of IRTA1 and T-bet as positive markers. <i>Histopathology</i> , 2013 , 63, 482-98	7.3	23
258	A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice. <i>Leukemia</i> , 2013 , 27, 1917-20	10.7	56
257	Lymphoma classification: past, present and future 2013 , 6-30		
256	The human NPM1 mutation A perturbs megakaryopoiesis in a conditional mouse model. <i>Blood</i> , 2013 , 121, 3447-58	2.2	25
255	Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia. <i>Haematologica</i> , 2013 , 98, 635-9	6.6	60
254	IL-17-producing double-negative T cells are expanded in the peripheral blood, infiltrate the salivary gland and are partially resistant to corticosteroid therapy in patients with Sjögren's syndrome. <i>Reumatismo</i> , 2013 , 65, 192-8	1.1	11

253	Targeting The BRAF-MEK-ERK Pathway In Hairy Cell Leukemia. <i>Blood</i> , 2013 , 122, 3064-3064	2.2	3
252	Long-Term Health Related Quality Of Life and Symptom Burden In Patients With Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid (ATRA) and Chemotherapy. <i>Blood</i> , 2013 , 122, 770-770	2.2	2
251	Molecular Lesions Of Signalling Pathway Genes In Indolent B-Cell Lymphoproliferations Mimicking Splenic Marginal Zone Lymphoma. <i>Blood</i> , 2013 , 122, 4250-4250	2.2	0
250	IRTA1 is selectively expressed in nodal and extranodal marginal zone lymphomas. <i>Histopathology</i> , 2012 , 61, 930-41	7.3	73
249	Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. <i>Blood</i> , 2012 , 119, 192-5	2.2	140
248	Absence of BRAF-V600E in the human cell lines BONNA-12, ESKOL, HAIR-M, and HC-1 questions their origin from hairy cell leukemia. <i>Blood</i> , 2012 , 119, 5332-3	2.2	15
247	A microRNA signature specific for hairy cell leukemia and associated with modulation of the MAPK-JNK pathways. <i>Leukemia</i> , 2012 , 26, 2564-7	10.7	11
246	The BRAF-V600E mutation in hematological malignancies: a new player in hairy cell leukemia and Langerhans cell histiocytosis. <i>Leukemia and Lymphoma</i> , 2012 , 53, 2339-40	1.9	11
245	Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma. <i>Blood</i> , 2012 , 120, 4609-20	2.2	115
244	T regulatory cell separation for clinical application. <i>Transfusion and Apheresis Science</i> , 2012 , 47, 213-6	2.4	32
243	The NPM1 wild-type OCI-AML2 and the NPM1-mutated OCI-AML3 cell lines carry DNMT3A mutations. <i>Leukemia</i> , 2012 , 26, 554-7	10.7	32
242	Constant Activation of the RAF-MEK-ERK Pathway As a Diagnostic and Therapeutic Target in Hairy Cell Leukemia.. <i>Blood</i> , 2012 , 120, 2657-2657	2.2	
241	Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. <i>Blood</i> , 2011 , 117, 3921-8	2.2	821
240	Immunoselection and clinical use of T regulatory cells in HLA-haploidentical stem cell transplantation. <i>Best Practice and Research in Clinical Haematology</i> , 2011 , 24, 459-66	4.2	37
239	Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy?. <i>Blood Reviews</i> , 2011 , 25, 247-54	11.1	64
238	Lymphoma classification: the quiet after the storm. <i>Seminars in Diagnostic Pathology</i> , 2011 , 28, 113-23	4.3	17
237	Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?. <i>Blood</i> , 2011 , 117, 1109-20	2.2	178
236	NPM1-mutated AML: targeting by disassembling. <i>Blood</i> , 2011 , 118, 2936-8	2.2	12

235	High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation. <i>Haematologica</i> , 2011 , 96, 1548-51	6.6	55
234	Low prevalence of IDH1 gene mutation in childhood AML in Italy. <i>Leukemia</i> , 2011 , 25, 173-4	10.7	7
233	Chronic eosinophilic leukaemia with ETV6-NTRK3 fusion transcript in an elderly patient affected with pancreatic carcinoma. <i>European Journal of Haematology</i> , 2011 , 86, 352-5	3.8	15
232	Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. <i>Blood</i> , 2011 , 118, 6153-63	2.2	191
231	BRAF mutations in hairy-cell leukemia. <i>New England Journal of Medicine</i> , 2011 , 364, 2305-15	59.2	791
230	A case of JAK2 V617F-positive myelodysplastic/myeloproliferative neoplasm with unusual morphology, resembling acute promyelocytic leukemia-like disorder with a chronic course. <i>Leukemia and Lymphoma</i> , 2011 , 52, 2012-9	1.9	0
229	Pathobiology of ALK-negative anaplastic large cell lymphoma. <i>Mental Illness</i> , 2011 , 3 Suppl 2, e5	0.9	7
228	Histone Deacetylase Inhibitors Induce Cell Growth Inhibition and Apoptosis in NPM1-Mutated AML Cells: A Possible Role for Epigenetic Therapies in AML Carrying NPM1 Gene Mutations. <i>Blood</i> , 2011 , 118, 2621-2621	2.2	
227	Whole-Exome Sequencing Identifies Recurrent Mutations of BCOR in Acute Myeloid Leukemia with Normal Karyotype. <i>Blood</i> , 2011 , 118, 71-71	2.2	1
226	Rapid flow cytometric detection of aberrant cytoplasmic localization of nucleophosmin (NPMc) indicating mutant NPM1 gene in acute myeloid leukemia. <i>Leukemia</i> , 2010 , 24, 1813-6	10.7	17
225	NPM1 deletion is associated with gross chromosomal rearrangements in leukemia. <i>PLoS ONE</i> , 2010 , 5, e12855	3.7	16
224	Immunohistochemical surrogates for genetic alterations of CCDN1, PML, ALK, and NPM1 genes in lymphomas and acute myeloid leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2010 , 23, 417-31	4.2	8
223	EML4-ALK fusion in lung. <i>American Journal of Pathology</i> , 2010 , 176, 1552-3; author reply 1553-4	5.8	13
222	Nucleophosmin C-terminal leukemia-associated domain interacts with G-rich quadruplex forming DNA. <i>Journal of Biological Chemistry</i> , 2010 , 285, 37138-49	5.4	48
221	Characterization of a new monoclonal antibody against PAX5/BASP in 1525 paraffin-embedded human and animal tissue samples. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2010 , 18, 561-72	1.9	22
220	Expression of the cytoplasmic NPM1 mutant (NPMc+) causes the expansion of hematopoietic cells in zebrafish. <i>Blood</i> , 2010 , 115, 3329-40	2.2	61
219	CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. <i>Blood</i> , 2010 , 116, 3907-22	2.2	83
218	Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). <i>Blood</i> , 2010 , 115, 3776-86	2.2	91

217	Low Prevalence of IDH1 gene Mutation In Childhood AML In Italy.. <i>Blood</i> , 2010 , 116, 1678-1678	2.2	
216	Acute myeloid leukemia with mutated nucleophosmin (NPM1): molecular, pathological, and clinical features. <i>Cancer Treatment and Research</i> , 2010 , 145, 149-68	3.5	11
215	New classification of acute myeloid leukemia and precursor-related neoplasms: changes and unsolved issues. <i>Discovery Medicine</i> , 2010 , 10, 281-92	2.5	17
214	Cytoplasmic nucleophosmin is not detected in blastic plasmacytoid dendritic cell neoplasm. <i>Haematologica</i> , 2009 , 94, 285-8	6.6	31
213	Folding mechanism of the C-terminal domain of nucleophosmin: residual structure in the denatured state and its pathophysiological significance. <i>FASEB Journal</i> , 2009 , 23, 2360-5	0.9	30
212	Mantle cell lymphoma. <i>Haematologica</i> , 2009 , 94, 1488-92	6.6	66
211	Cuplike nuclei (prominent nuclear invaginations) in acute myeloid leukemia are highly associated with FLT3 internal tandem duplication and NPM1 mutation. <i>Cancer</i> , 2009 , 115, 5481-9	6.4	52
210	Immunohistochemical and other prognostic factors in B cell non Hodgkin lymphoma patients, Kampala, Uganda. <i>BMC Clinical Pathology</i> , 2009 , 9, 11	3	12
209	Simultaneous occurrence of acute myeloid leukaemia with mutated nucleophosmin (NPM1) in the same family. <i>Leukemia</i> , 2009 , 23, 199-203	10.7	5
208	A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF. <i>Leukemia</i> , 2009 , 23, 501-9	10.7	59
207	Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. <i>Leukemia</i> , 2009 , 23, 1731-43	10.7	156
206	Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma. <i>Leukemia</i> , 2009 , 23, 2129-38	10.7	109
205	Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia. <i>Leukemia</i> , 2009 , 23, 1370-1	10.7	12
204	Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. <i>Blood</i> , 2009 , 114, 2220-31	2.2	269
203	EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. <i>American Journal of Pathology</i> , 2009 , 174, 661-70	5.8	261
202	Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives. <i>Current Opinion in Oncology</i> , 2009 , 21, 573-81	4.2	67
201	The EML4-ALK transcript but not the fusion protein can be expressed in reactive and neoplastic lymphoid tissues. <i>Haematologica</i> , 2009 , 94, 1307-11	6.6	15
200	Response: NPM1-mutated AML is an entity irrespective of whether or not chromosomal aberrations are present. <i>Blood</i> , 2009 , 114, 4602-4603	2.2	3

199	AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. <i>Blood</i> , 2009 , 114, 3024-32	2.2	139
198	New Pathogenetic Insights Into Classical Hodgkin Lymphoma Revealed by Gene Expression Profiling of Microdissected Hodgkin/Reed-Sternberg Cells.. <i>Blood</i> , 2009 , 114, 266-266	2.2	1
197	Late relapse of acute myeloid leukemia with mutated NPM1 after eight years: evidence of NPM1 mutation stability. <i>Haematologica</i> , 2009 , 94, 298-300	6.6	10
196	The Presence of Multilineage Dysplasia (MLD) Has No Significant Impact On Biological, Clinico-Pathological, and Prognostic Features in AML with Mutated Nucleophosmin (NPM1).. <i>Blood</i> , 2009 , 114, 2618-2618	2.2	
195	De-Regulation of MicroRNA Expression Is Detected in Hairy Cell Leukemia.. <i>Blood</i> , 2009 , 114, 3462-3462	2.2	
194	Acute Myeloid Leukemia with Mutated NPM1 Presenting with Life-Threatening, Either Arterial or Venous, Thromboembolism: a Report of 4 Cases.. <i>Blood</i> , 2009 , 114, 4135-4135	2.2	
193	Dissecting the Hierarchical Level of Hematopoietic Progenitors' Involvement in AML with NPM1 Gene Mutation and Their Engraftment Potential in Immunocompromised Mice.. <i>Blood</i> , 2009 , 114, 480-480 ²	2.2	
192	A western blot assay for detecting mutant nucleophosmin (NPM1) proteins in acute myeloid leukaemia. <i>Leukemia</i> , 2008 , 22, 2285-8	10.7	20
191	Absence of nucleophosmin leukaemic mutants in B and T cells from AML with NPM1 mutations: implications for the cell of origin of NPMc+ AML. <i>Leukemia</i> , 2008 , 22, 195-8	10.7	21
190	Nucleophosmin leukaemic mutants contain C-terminus peptides that bind HLA class I molecules. <i>Leukemia</i> , 2008 , 22, 424-6	10.7	17
189	In human genome, generation of a nuclear export signal through duplication appears unique to nucleophosmin (NPM1) mutations and is restricted to AML. <i>Leukemia</i> , 2008 , 22, 1285-9	10.7	36
188	NPM1-mutated acute myeloid leukaemia occurring in JAK2-V617F+ primary myelofibrosis: de-novo origin?. <i>Leukemia</i> , 2008 , 22, 1459-63	10.7	14
187	Acute Myeloid Leukemia with Mutated Nucleophosmin. <i>Clinical Leukemia</i> , 2008 , 2, 163-173		1
186	A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1). <i>Haematologica</i> , 2008 , 93, 1219-26	6.6	20
185	NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia. <i>Haematologica</i> , 2008 , 93, 439-42	6.6	66
184	Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. <i>Journal of Experimental Medicine</i> , 2008 , 205, 2251-68	16.6	247
183	Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 3945-50	11.5	426
182	Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas. <i>Haematologica</i> , 2008 , 93, 1033-8	6.6	59

181	Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice. <i>Haematologica</i> , 2008 , 93, 775-9	6.6	42
180	Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia. <i>Haematologica</i> , 2008 , 93, 1017-24	6.6	16
179	Evidence for CD34+ Hematopoietic Progenitor Cell Involvement in Acute Myeloid Leukemia with NPM1 Gene Mutation: Implications for the Cell of Origin. <i>Blood</i> , 2008 , 112, 307-307	2.2	1
178	About 17% of AML with NPM1 mutations Show a Specific Pattern of Chromosome Aberrations but These Cases Do Not Differ Prognostically from AML with NPM1 Mutations Carrying a Normal Karyotype. <i>Blood</i> , 2008 , 112, 2527-2527	2.2	
177	The Detection of Multilineage Dysplasia (MLD) Has No Influence on Prognosis in NPM1 Mutated Acute Myeloid Leukemia (AML) with Normal Karyotype. <i>Blood</i> , 2008 , 112, 2518-2518	2.2	
176	CXCR4 as a Predictor of Response in Acute Myeloid Leukemia. <i>Blood</i> , 2008 , 112, 2941-2941	2.2	
175	Molecular Monitoring of Acute Myeloid Leukemia Patients Carrying Nucleophosmin (NPM1) Mutations Undergoing An Autologous Peripheral Blood Stem Cell Transplantation. <i>Blood</i> , 2008 , 112, 4864-4864	2.2	
174	Any role for the nucleophosmin (NPM1) gene in myelodysplastic syndromes and acute myeloid leukemia with chromosome 5 abnormalities?. <i>Leukemia and Lymphoma</i> , 2007 , 48, 2093-5	1.9	10
173	Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. <i>Leukemia</i> , 2007 , 21, 340-50	10.7	470
172	Identification and functional characterization of a cytoplasmic nucleophosmin leukaemic mutant generated by a novel exon-11 NPM1 mutation. <i>Leukemia</i> , 2007 , 21, 1099-103	10.7	46
171	Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas. <i>Leukemia</i> , 2007 , 21, 1566-70	10.7	97
170	Molecular detection of GNNK- and GNNK+ c-kit isoforms: a new tool for risk stratification in adult acute myeloid leukaemia. <i>Leukemia</i> , 2007 , 21, 2056-8	10.7	5
169	Reply to Pitiot et al. <i>Leukemia</i> , 2007 , 21, 2055-2056	10.7	2
168	Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. <i>Blood</i> , 2007 , 109, 874-85	2.2	415
167	Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. <i>Haematologica</i> , 2007 , 92, 519-32	6.6	156
166	Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants. <i>Cancer Research</i> , 2007 , 67, 6230-7	10.1	81
165	Diffuse Large B-Cell Lymphomas of the Waldeyer's Ring Frequently Have a Germinal Center-Like Phenotype: A Clinico-Pathological Study of 209 Patients from the Groupe d'Etude des Lymphomes de L'Adulte (GELA).. <i>Blood</i> , 2007 , 110, 1561-1561	2.2	1
164	Gene Expression Analysis of Follicular Lymphoma Provides a Potential Rationale for Histological Grading Revision.. <i>Blood</i> , 2007 , 110, 186-186	2.2	

163	Function of Nucleophosmin in Zebrafish Hematopoiesis.. <i>Blood</i> , 2007 , 110, 2644-2644	2.2	
162	One-Mutation Model Can Explain Age Incidence in AML Carrying Nucleophosmin (NPM1) Mutations.. <i>Blood</i> , 2007 , 110, 4312-4312	2.2	
161	Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2472-9	2.2	295
160	Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after diagnosis of acute myeloid leukaemia. <i>Lancet Oncology, The</i> , 2006 , 7, 350-2	21.7	24
159	Denaturing high-performance liquid chromatography: a valid approach for identifying NPM1 mutations in acute myeloid leukemia. <i>Journal of Molecular Diagnostics</i> , 2006 , 8, 254-9	5.1	31
158	Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma. <i>Blood</i> , 2006 , 108, 1013-20	2.2	59
157	Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. <i>Blood</i> , 2006 , 107, 4514-23	2.2	201
156	Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. <i>Blood</i> , 2006 , 108, 1999-2005	2.2	146
155	Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification. <i>Blood</i> , 2006 , 108, 4146-55	2.2	82
154	Nucleophosmin and cancer. <i>Nature Reviews Cancer</i> , 2006 , 6, 493-505	31.3	648
153	Evolving concepts in the pathogenesis of hairy-cell leukaemia. <i>Nature Reviews Cancer</i> , 2006 , 6, 437-48	31.3	79
152	Aberrant subcellular expression of nucleophosmin and NPM-MLF1 fusion protein in acute myeloid leukaemia carrying t(3;5): a comparison with NPMc+ AML. <i>Leukemia</i> , 2006 , 20, 368-71	10.7	37
151	Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. <i>Leukemia</i> , 2006 , 20, 1103-8	10.7	234
150	Reciprocal Interaction between NPM Leukemic Mutants and Arf: Structural Basis and Functional Consequences.. <i>Blood</i> , 2006 , 108, 1939-1939	2.2	
149	Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. <i>New England Journal of Medicine</i> , 2005 , 352, 254-66	59.2	1374
148	Epstein-barr virus infection of monocytoid B-cell proliferates: an early feature of primary viral infection?. <i>American Journal of Surgical Pathology</i> , 2005 , 29, 595-601	6.7	4
147	Tumor protein D52 (TPD52): a novel B-cell/plasma-cell molecule with unique expression pattern and Ca(2+)-dependent association with annexin VI. <i>Blood</i> , 2005 , 105, 2812-20	2.2	34
146	Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. <i>Blood</i> , 2005 , 106, 899-902	2.2	253

145	Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. <i>Blood</i> , 2005 , 106, 1419-22	2.2	133
144	Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. <i>Blood</i> , 2005 , 106, 3733-9	2.2	571
143	Computational modeling of the immune response to tumor antigens. <i>Journal of Theoretical Biology</i> , 2005 , 237, 390-400	2.3	20
142	Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia. <i>Leukemia</i> , 2005 , 19, 1479-82	10.7	102
141	Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. <i>Leukemia</i> , 2005 , 19, 1760-7	10.7	124
140	Interleukin 7-engineered stromal cells: a new approach for hastening naive T cell recruitment. <i>Human Gene Therapy</i> , 2005 , 16, 752-64	4.8	6
139	Nucleophosmin is required for DNA integrity and p19Arf protein stability. <i>Molecular and Cellular Biology</i> , 2005 , 25, 8874-86	4.8	174
138	Nucleophosmin Gene Mutations Are Predictors of Favourable Prognosis in Acute Myeloid Leukemia with a Normal Kayotype and Can Be Used as a New Marker for Quantitative PCR To Detect Minimal Residual Disease.. <i>Blood</i> , 2005 , 106, 223-223	2.2	1
137	Exon-12 Nucleophosmin (NPM) Mutation and Aberrant Cytoplasmic Expression of NPM Protein in Leukemia Cell Line OCI-AML3.. <i>Blood</i> , 2005 , 106, 2376-2376	2.2	
136	Marker Expression in Peripheral T-Cell Lymphoma Unspecified: Proposal of a Clinical-Pathologic Prognostic Score.. <i>Blood</i> , 2005 , 106, 2819-2819	2.2	
135	Mechanism of Altered Nucleo-Cytoplasmic Traffic of Nucleophosmin in Acute Myelogenous Leukemia Carrying Exon-12 NPM Mutations (NPMc+ AML).. <i>Blood</i> , 2005 , 106, 4396-4396	2.2	
134	Quantitative Detection of NPM1 Mutations as Marker of Minimal Residual Disease (MRD) in the Large Majority of AML with Normal Karyotype.. <i>Blood</i> , 2005 , 106, 225-225	2.2	
133	Gene Expression Analysis of Peripheral T-Cell Lymphoma Not Otherwise Specified Reveals the Existance of Two Subgroups Related to Different Cellular Counterparts and Recurrent PDGFRA Deregulation.. <i>Blood</i> , 2005 , 106, 1217-1217	2.2	1
132	Modulatory effects of mycobacterial heat-shock protein 70 in DNA vaccination against lymphoma. <i>Haematologica</i> , 2005 , 90, 60-5	6.6	8
131	Lymphoplasmacytic lymphoma and marginal zone lymphoma: diagnostic challenges. <i>Haematologica</i> , 2005 , 90, 148	6.6	3
130	Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. <i>Haematologica</i> , 2005 , 90, 341-7	6.6	40
129	T-bet-positive and IRTA1-positive monocytoid B cells differ from marginal zone B cells and epithelial-associated B cells in their antigen profile and topographical distribution. <i>Haematologica</i> , 2005 , 90, 1070-7	6.6	29
128	Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors. <i>Journal of Experimental Medicine</i> , 2004 , 199, 59-68	16.6	161

127	Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2654-61	2.2	123
126	PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia. <i>Cancer Research</i> , 2004 , 64, 7399-404	10.1	89
125	Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. <i>Blood</i> , 2004 , 103, 275-82	2.2	2955
124	Treating two concurrent B-cell and T-cell lymphoid neoplasms with alemtuzumab monotherapy. <i>Lancet Oncology, The</i> , 2004 , 5, 64-5	21.7	9
123	Haploidentical peripheral-blood stem-cell transplantation for ALK-positive anaplastic large-cell lymphoma. <i>Lancet Oncology, The</i> , 2004 , 5, 127-8	21.7	14
122	Nodal marginal-zone lymphoma associated with monoclonal light-chain and heavy-chain deposition disease. <i>Lancet Oncology, The</i> , 2004 , 5, 381-3	21.7	13
121	Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). <i>Lancet, The</i> , 2004 , 363, 1869-70	40	194
120	Anaplastic Large Cell Lymphoma: A Critical Reappraisal. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2004 , 44, 41-52	1.9	
119	Tumor Protein D52 (TPD52): A Novel B Cell/Plasma Cell Molecule Identified through a Proteomic Approach and Characterized by Unique Expression Pattern and Ca ²⁺ -Dependent Association with Annexin VI.. <i>Blood</i> , 2004 , 104, 3652-3652	2.2	
118	Leukocyte-specific phosphoprotein-1 and PU.1: two useful markers for distinguishing T-cell-rich B-cell lymphoma from lymphocyte-predominant Hodgkin's disease. <i>Haematologica</i> , 2004 , 89, 957-64	6.6	20
117	Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. <i>Journal of Clinical Oncology</i> , 2003 , 21, 1255-62	2.2	109
116	Pathobiology of primary mediastinal B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2003 , 44 Suppl 3, S21-6	1.9	48
115	Expression of the IRTA1 receptor identifies intraepithelial and subepithelial marginal zone B cells of the mucosa-associated lymphoid tissue (MALT). <i>Blood</i> , 2003 , 102, 3684-92	2.2	89
114	Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. <i>American Journal of Pathology</i> , 2003 , 162, 243-53	5.8	137
113	Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2003 , 101, 78-84	2.2	322
112	Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification. <i>Histopathology</i> , 2002 , 41, 482-509	7.3	65
111	Homing and survival of thymidine kinase-transduced human T cells in NOD/SCID mice. <i>Cancer Gene Therapy</i> , 2002 , 9, 756-61	5.4	9
110	Nucleophosmin regulates the stability and transcriptional activity of p53. <i>Nature Cell Biology</i> , 2002 , 4, 529-33	23.4	431

109	Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients. <i>Annals of Oncology</i> , 2002 , 13, 1364-9	10.3	15
108	Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. <i>Blood</i> , 2002 , 99, 409-26	2.2	155
107	Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity. <i>American Journal of Pathology</i> , 2002 , 160, 1487-94	5.8	95
106	Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin. <i>Cancer Research</i> , 2002 , 62, 1559-66	10.1	101
105	Relevance of CD79a expression for T-cell lineage attribution in CD7+/CD3- acute lymphoblastic leukemia. <i>Haematologica</i> , 2002 , 87, ELT41	6.6	1
104	Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. <i>Haematologica</i> , 2002 , 87, 1258-64	6.6	124
103	Diffuse large B-cell lymphoma (DLBCL), anaplastic variant. report on a problematic case primarily arising in the stomach. <i>Haematologica</i> , 2002 , 87, ECR40	6.6	
102	Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. <i>Blood</i> , 2001 , 97, 496-501	2.2	230
101	Expression of bcl-6 and CD10 in primary mediastinal large B-cell lymphoma: evidence for derivation from germinal center B cells?. <i>American Journal of Surgical Pathology</i> , 2001 , 25, 1277-82	6.7	66
100	Anaplastic large cell lymphoma: pathological, molecular and clinical features. <i>British Journal of Haematology</i> , 2001 , 114, 741-60	4.5	106
99	Vaccine therapy of B cell malignancies: different strategies for a novel approach. <i>Leukemia and Lymphoma</i> , 2001 , 42, 881-9	1.9	1
98	Myeloperoxidase expression by histiocytes in Kikuchi's and Kikuchi-like lymphadenopathy. <i>American Journal of Pathology</i> , 2001 , 159, 915-24	5.8	71
97	Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry. <i>Modern Pathology</i> , 2001 , 14, 686-94	9.8	152
96	Diffuse large B-cell lymphoma with primary retroperitoneal presentation: clinico-pathologic study of nine cases. <i>Annals of Oncology</i> , 2001 , 12, 1445-53	10.3	12
95	Expression of the ALK protein by anaplastic large-cell lymphomas correlates with high proliferative activity. <i>International Journal of Cancer</i> , 2000 , 86, 777-81	7.5	8
94	Defective recruitment and activation of ZAP-70 in common variable immunodeficiency patients with T cell defects. <i>European Journal of Immunology</i> , 2000 , 30, 2632-8	6.1	52
93	A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. <i>Blood</i> , 2000 , 95, 2084-2092	2.2	366
92	Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma. <i>Blood</i> , 2000 , 96, 1605-1607	2.2	90

91	Rapid diagnosis of acute promyelocytic leukemia by analyzing the immunocytochemical pattern of the PML protein with the monoclonal antibody PG-M3. <i>American Journal of Clinical Pathology</i> , 2000 , 114, 786-92	1.9	25
90	Immunophenotypic and genotypic markers of follicular center cell neoplasia in diffuse large B-cell lymphomas. <i>Modern Pathology</i> , 2000 , 13, 1219-31	9.8	59
89	CD30+ T cells in rheumatoid synovitis: mechanisms of recruitment and functional role. <i>Journal of Immunology</i> , 2000 , 164, 4399-407	5.3	52
88	Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma. <i>Blood</i> , 2000 , 96, 1605-1607	2.2	3
87	T-cell prolymphocytic leukaemia: does the expression of CD8+ phenotype justify the identification of a new subtype? Description of two cases and review of the literature. <i>Annals of Oncology</i> , 1999 , 10, 649-53	10.3	14
86	TRK-Fused Gene (TFG) Is a New Partner of ALK in Anaplastic Large Cell Lymphoma Producing Two Structurally Different TFG-ALK Translocations. <i>Blood</i> , 1999 , 94, 3265-3268	2.2	238
85	Detection of Normal and Chimeric Nucleophosmin in Human Cells. <i>Blood</i> , 1999 , 93, 632-642	2.2	94
84	Genetic Diagnosis and Molecular Monitoring in the Management of Acute Promyelocytic Leukemia. <i>Blood</i> , 1999 , 94, 12-22	2.2	173
83	Acute leukaemia immunophenotyping in bone-marrow routine sections. <i>British Journal of Haematology</i> , 1999 , 105, 394-401	4.5	48
82	Gene rearrangements in T-cell lymphoblastic lymphoma. <i>Journal of Pathology</i> , 1999 , 188, 267-70	9.4	49
81	Biochemical detection of novel anaplastic lymphoma kinase proteins in tissue sections of anaplastic large cell lymphoma. <i>American Journal of Pathology</i> , 1999 , 154, 1657-63	5.8	47
80	Detection of Normal and Chimeric Nucleophosmin in Human Cells. <i>Blood</i> , 1999 , 93, 632-642	2.2	8
79	Beta-HCG aberrant expression in primary mediastinal large B-cell lymphoma. <i>American Journal of Surgical Pathology</i> , 1999 , 23, 717-21	6.7	14
78	Co-expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma. <i>Journal of Pathology</i> , 1998 , 186, 140-3	9.4	92
77	Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): in vitro and in vivo studies. <i>British Journal of Haematology</i> , 1998 , 101, 179-88	4.5	32
76	ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. <i>American Journal of Pathology</i> , 1998 , 153, 875-86	5.8	219
75	Induction of the pro-myelocytic leukaemia gene by type I and type II interferons. <i>Mediators of Inflammation</i> , 1998 , 7, 319-25	4.3	12
74	The Cryptic inv(2)(p23q35) Defines a New Molecular Genetic Subtype of ALK-Positive Anaplastic Large-Cell Lymphoma. <i>Blood</i> , 1998 , 92, 2688-2695	2.2	82

73	Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. <i>New England Journal of Medicine</i> , 1997 , 337, 453-8	59.2	273
72	Bcl-6 protein expression in normal and neoplastic lymphoid tissue. <i>Annals of Oncology</i> , 1997 , 8, S101-S104	6.3	33
71	Immunohistochemistry of bone-marrow biopsy. <i>Leukemia and Lymphoma</i> , 1997 , 26 Suppl 1, 69-75	1.9	10
70	Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification. <i>Annals of Oncology</i> , 1997 , 8, 583-92	10.3	104
69	Immunocytochemical Diagnosis of Acute Promyelocytic Leukemia (M3) With the Monoclonal Antibody PG-M3 (Anti-PML). <i>Blood</i> , 1997 , 90, 4046-4053	2.2	113
68	BCL-6 Protein Expression in Human Peripheral T-Cell Neoplasms Is Restricted to CD30+ Anaplastic Large-Cell Lymphomas. <i>Blood</i> , 1997 , 90, 2445-2450	2.2	42
67	Lack of correlation between membrane CD30 expression and cytokine secretion pattern in allergen-primed naive cord blood T-cell lines and clones. <i>Scandinavian Journal of Immunology</i> , 1997 , 45, 417-22	3.4	8
66	CD30+ anaplastic large-cell lymphoma, null type, with signet-ring appearance. <i>Histopathology</i> , 1997 , 30, 90-2	7.3	30
65	Antigen retrieval techniques in immunohistochemistry: comparison of different methods. <i>Journal of Pathology</i> , 1997 , 183, 116-23	9.4	231
64	Antigen retrieval techniques in immunohistochemistry: comparison of different methods 1997 , 183, 116		14
63	Molecular findings and classification of malignant lymphomas. <i>Acta Haematologica</i> , 1996 , 95, 181-7	2.7	4
62	Sch proteins are localized on endoplasmic reticulum membranes and are redistributed after tyrosine kinase receptor activation. <i>Molecular and Cellular Biology</i> , 1996 , 16, 1946-54	4.8	64
61	Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients. <i>Journal of Clinical Oncology</i> , 1996 , 14, 955-62	2.2	74
60	Anti-CD30 (BER-H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice. <i>British Journal of Haematology</i> , 1996 , 92, 872-9	4.5	47
59	Induction of apoptosis by ribosome-inactivating proteins and related immunotoxins. <i>International Journal of Cancer</i> , 1996 , 68, 349-55	7.5	71
58	Molecular Findings and Classification of Malignant Lymphomas 1996 , 135-144		
57	Mediastinal large B-cell lymphoma: clinical and immunohistological findings in 18 patients treated with different third-generation regimens. <i>British Journal of Haematology</i> , 1995 , 89, 780-9	4.5	61
56	MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas. <i>Leukemia and Lymphoma</i> , 1995 , 16, 457-63	1.9	15

55	Bone marrow findings further support the hypothesis that essential mixed cryoglobulinemia type II is characterized by a monoclonal B-cell proliferation. <i>Leukemia and Lymphoma</i> , 1995 , 20, 119-24	1.9	50
54	Is Hodgkin's disease a unique entity?. <i>Leukemia and Lymphoma</i> , 1995 , 15 Suppl 1, 3-6	1.9	6
53	Anaplastic large cell lymphoma: update of findings. <i>Leukemia and Lymphoma</i> , 1995 , 18, 17-25	1.9	37
52	A revised European-American classification of lymphoid neoplasms proposed by the International Lymphoma Study Group. A summary version. <i>American Journal of Clinical Pathology</i> , 1995 , 103, 543-60	1.9	99
51	Granular Cell Tumor: An Immunohistochemical Study. <i>Tumori</i> , 1994 , 80, 224-228	1.7	26
50	A proposal for classification of lymphoid neoplasms (by the International Lymphoma Study Group). <i>Histopathology</i> , 1994 , 25, 517-36	7.3	77
49	Lymphohistiocytic T-cell lymphoma. <i>Histopathology</i> , 1994 , 25, 191-3	7.3	11
48	Anaplastic large cell lymphoma (CD30 +/Ki-1+): results of a prospective clinico-pathological study of 69 cases. <i>British Journal of Haematology</i> , 1994 , 86, 513-23	4.5	85
47	Apoptosis as programmed cell death (PCD): Cupio dissolvi in cell life. <i>Current Diagnostic Pathology</i> , 1994 , 1, 48-55		10
46	Comparison between the monoclonal antibodies Ki-67 and PC10 in 125 malignant lymphomas. <i>Journal of Pathology</i> , 1993 , 169, 397-403	9.4	43
45	Lymphotoxin, tumour necrosis factor and interleukin-6 gene transcripts are present in Hodgkin and Reed-Sternberg cells of most Hodgkin's disease cases. <i>British Journal of Haematology</i> , 1993 , 84, 627-35	4.5	80
44	High Serum Levels of Soluble Interleukin-2 Receptor and Absence of Detectable Levels of Soluble CD30 Molecule: A Specific Diagnostic Combination for Hairy Cell Leukemia. <i>Leukemia and Lymphoma</i> , 1992 , 6, 385-388	1.9	2
43	Hairy cell leukemia. Diagnosis of bone marrow involvement in paraffin-embedded sections with monoclonal antibody DBA.44. <i>American Journal of Clinical Pathology</i> , 1992 , 98, 26-33	1.9	73
42	Lymphohistiocytic T-cell Lymphoma and Peripheral T-cell Lymphoma Associated with Haemophagocytic Syndrome: Two Recently Recognized Entities Which Mimic Malignant Histiocytosis. <i>Leukemia and Lymphoma</i> , 1992 , 6, 317-324	1.9	8
41	Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. <i>Lancet, The</i> , 1992 , 339, 1195-6	4.0	184
40	Macrophages in normal human bone marrow and in chronic myeloproliferative disorders: an immunohistochemical and morphometric study by a new monoclonal antibody (PG-M1) on trephine biopsies. <i>Virchows Archiv A, Pathological Anatomy and Histopathology</i> , 1992 , 421, 33-9		41
39	In vivo targeting of Hodgkin and Reed-Sternberg cells of Hodgkin's disease with monoclonal antibody Ber-H2 (CD30): immunohistological evidence. <i>British Journal of Haematology</i> , 1992 , 82, 38-45	4.5	44
38	Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation. <i>British Journal of Haematology</i> , 1992 , 81, 203-11	4.5	68

37	Malignant lymphoma in the recipient of a heart transplant from a donor with malignant lymphoma. Lymphoma transplantation or de novo disease?. <i>Transplantation</i> , 1991 , 51, 920-2	1.8	12
36	Immunohistochemical detection of the multidrug transport protein P170 in human normal tissues and malignant lymphomas. <i>Histopathology</i> , 1991 , 19, 131-40	7.3	87
35	Expression of the intestinal T-lymphocyte associated molecule HML-1: analysis of 75 non-Hodgkin's lymphomas and description of the first HML-1 positive T-lymphoblastic tumour. <i>Histopathology</i> , 1991 , 18, 421-6	7.3	14
34	Rhabdomyosarcoma presenting as 'acute leukaemia'. <i>Histopathology</i> , 1991 , 19, 575-6	7.3	8
33	Lymphohistiocytic T-cell lymphoma (anaplastic large cell lymphoma CD30+/Ki-1 + with a high content of reactive histiocytes). <i>Histopathology</i> , 1990 , 16, 383-91	7.3	156
32	LF61: a new monoclonal antibody directed against a trimeric molecule (150 kDa, 125 kDa, 105 kDa) associated with hairy cell leukaemia. <i>British Journal of Haematology</i> , 1990 , 76, 451-9	4.5	18
31	Response to intermediate and standard doses of IFN-beta in hairy-cell leukaemia. <i>Leukemia Research</i> , 1990 , 14, 779-84	2.7	8
30	Variable expression of leucocyte-common (CD45) antigen in CD30 (Ki1)-positive anaplastic large-cell lymphoma: implications for the differential diagnosis between lymphoid and nonlymphoid malignancies. <i>Human Pathology</i> , 1990 , 21, 624-9	3.7	65
29	Evolutionary conservation in various mammalian species of the human proliferation-associated epitope recognized by the Ki-67 monoclonal antibody. <i>Journal of Histochemistry and Cytochemistry</i> , 1989 , 37, 1471-8	3.4	53
28	Histological and immunohistological analysis of human lymphomas. <i>Critical Reviews in Oncology/Hematology</i> , 1989 , 9, 351-419	7	34
27	Immunocytochemical evaluation of the percentage of proliferating cells in pathological bone marrow and peripheral blood samples with the Ki-67 and anti-bromo-deoxyuridine monoclonal antibodies. <i>British Journal of Haematology</i> , 1988 , 69, 311-20	4.5	41
26	Large cell lymphoma of bone. A report of three cases of B-cell origin. <i>Histopathology</i> , 1988 , 12, 177-90	7.3	20
25	Essential mixed cryoglobulinemia, type II: a manifestation of a low-grade malignant lymphoma? Clinical-morphological study of 12 cases with special reference to immunohistochemical findings in liver frozen sections. <i>Acta Haematologica</i> , 1988 , 79, 20-5	2.7	92
24	Histiocytic necrotizing lymphadenitis without granulocytic infiltration (Kikuchi's lymphadenitis). Morphological and immunohistochemical study of eight cases. <i>Histopathology</i> , 1987 , 11, 1013-27	7.3	41
23	ins(6;11) in a case of peripheral T-cell lymphoma. <i>Cancer Genetics and Cytogenetics</i> , 1987 , 27, 367-9		1
22	Expression of lymphoid-associated antigens on Hodgkin's and Reed-Sternberg cells of Hodgkin's disease. An immunocytochemical study on lymph node cytopins using monoclonal antibodies. <i>Histopathology</i> , 1987 , 11, 1229-42	7.3	93
21	Genotypic analysis of large cell lymphomas which express the Ki-1 antigen. <i>Histopathology</i> , 1987 , 11, 733-40	7.3	103
20	The AuthorsReply: We Agree. <i>American Journal of Clinical Pathology</i> , 1986 , 85, 253-254	1.9	1

19	Use of a panel of monoclonal antibodies for the diagnosis of hairy cell leukaemia. An immunocytochemical study of 36 cases. <i>Histopathology</i> , 1986 , 10, 671-87	7.3	40
18	T-cell receptor beta-chain gene rearrangement in a case of Ph1-positive chronic myeloid leukemia blast crisis. <i>British Journal of Haematology</i> , 1986 , 62, 776-9	4.5	19
17	Phytohemagglutinin-conditioned medium modulates adherence properties and morphology of hairy cells. <i>Leukemia Research</i> , 1986 , 10, 1091-9	2.7	2
16	Description of a sequential staining procedure for double immunoenzymatic staining of pairs of antigens using monoclonal antibodies. <i>Journal of Immunological Methods</i> , 1986 , 93, 265-73	2.5	43
15	The differential diagnosis of hairy cell leukemia with a panel of monoclonal antibodies. <i>American Journal of Clinical Pathology</i> , 1985 , 83, 289-300	1.9	51
14	Detection of metastatic tumour cells in routine bone marrow smears by immuno-alkaline phosphatase labelling with monoclonal antibodies. <i>British Journal of Haematology</i> , 1985 , 61, 21-30	4.5	34
13	Immunohistological analysis of human bone marrow trephine biopsies using monoclonal antibodies. <i>British Journal of Haematology</i> , 1984 , 56, 365-86	4.5	57
12	Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). <i>Journal of Histochemistry and Cytochemistry</i> , 1984 , 32, 219-29	3.4	2942
11	Single and double immunoenzymatic techniques for labeling tissue sections with monoclonal antibodies. <i>Annals of the New York Academy of Sciences</i> , 1983 , 420, 127-33	6.5	23
10	Diagnosis of human lymphoma with monoclonal antileukocyte antibodies. <i>New England Journal of Medicine</i> , 1983 , 309, 1275-81	59.2	344
9	Multiple myeloma with a sarcoidosis-like reaction. <i>Scandinavian Journal of Haematology</i> , 1982 , 29, 211-6		5
8	Double labeled-antigen method for demonstration of intracellular antigens in paraffin-embedded tissues. <i>Journal of Histochemistry and Cytochemistry</i> , 1982 , 30, 21-6	3.4	36
7	Intracytoplasmic Lysozyme in Malignant Hematologic Disorders: An Immunoperoxidase Study. <i>Tumori</i> , 1982 , 68, 417-425	1.7	3
6	Sideroblastic anemia associated with hairy cell leukemia. <i>Cancer</i> , 1981 , 48, 762-7	6.4	2
5	Light chain plasmacytoid lymphocytic lymphoma. <i>Postgraduate Medical Journal</i> , 1981 , 57, 588-91	2	
4	Prolymphocytic leukaemia with erythrophagocytic activity. <i>British Journal of Haematology</i> , 1980 , 46, 141-2	4.5	8
3	Erythrophagocytosis by undifferentiated lung carcinoma cells. <i>Cancer</i> , 1980 , 46, 1140-5	6.4	47
2	Topographical localization of intracellular immunoglobulins in hairy cells by immunoelectron microscopy. <i>Acta Haematologica</i> , 1980 , 64, 251-5	2.7	3

- 1 Protein A-peroxidase conjugates for two-stage immunoenzyme staining of intracellular antigens in paraffin-embedded tissues. *Journal of Immunological Methods*, **1980**, 39, 111-20 2.5 4